Provider-Payer Tug-of-War Takes Shape over FY2027 Drug Price Revision
To read the full story
Related Article
- Chuikyo Weighs “Agile Response” to MFN as Providers Question Drug Lag, Loss Impact
November 12, 2026
- FY2027 Revision: HCPs Press for Action on Drug Shortages, Negative Margins
October 29, 2026
- MHLW to Weigh Survey Data, Past Approach for FY2027 Revision: Official
September 10, 2026
- Pharma Seeks Inflation-Liked Price Hikes, Freeze on Patent-Period Cuts for 2027 Revision
August 27, 2026
- Chuikyo Kicks Off Debate on FY2027 Off-Year Drug Price Revision
July 9, 2026
REGULATORY
- Japan Approves Boey, Wider Labels for Hernexeos, Rinvoq, Tukysa, Pluvicto, and More
November 17, 2026
- Novartis Sjögren’s Drug, Meiji Antibiotic and More Up for Nov. 30 Panel Review
November 17, 2026
- Japan Grants Orphan Status to Rusfertide, Surovatamig, and Lots More
November 17, 2026
- Japan Extends Re-Examination for Saphnelo, Airwin, Fabhalta, Uplizna
November 17, 2026
- Takeda’s CLDN18.2 ADC Earns Sakigake Tag in Japan
November 17, 2026
Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…





